Clinical Trial Update: A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity. [Phase 1]

View source ↗

Summary

Phase 1 study to assess adverse events, tolerability, and pharmacokinetics of subcutaneous ABBV-295 in healthy adult Japanese participants with overweight or ob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• ABBV-295

Snippet

Sponsor: AbbVie | Conditions: Healthy Volunteer | Phase 1 | Status: RECRUITING